OBJECTIVE:Soluble receptor levels of tumor necrosis factor (sTNF-R)-1 and -2 are increased during preeclampsia. We postulated the increase preceded overt disease. STUDY DESIGN: Archived plasma from the Eunice Kennedy Shriver National Institute of Child Health and Human Development aspirin to prevent preeclampsia in high risk women trial were used to measure serial sTNF-R1 and sTNF-R2 (enrollment, 24-28 week's gestation) in 986 women (577 also sampled at 34-38 weeks). RESULTS:Preeclampsia incidence was 21.2%. sTNF-R2 levels were higher at enrollment (P = .02) and weeks 24-28 (P = .01) in women who eventually developed preeclampsia. The magnitude of increase from baseline of both receptors was significantly greater in women who developed preeclampsia in the future. Women with week 24-28 sTNF-R2 levels in the highest quartile had significantly increased odds to develop preeclampsia (P = .03 vs quartile 1). This association was observed in the placebo but not the aspirin arm (P <or= .002). Sensitivities and positive predictive values were low. CONCLUSION:sTNF-R2 levels are elevated prior to overt preeclampsia, suggesting a pathogenetic role for these proinflammatory cytokines.
RCT Entities:
OBJECTIVE: Soluble receptor levels of tumor necrosis factor (sTNF-R)-1 and -2 are increased during preeclampsia. We postulated the increase preceded overt disease. STUDY DESIGN: Archived plasma from the Eunice Kennedy Shriver National Institute of Child Health and Human Development aspirin to prevent preeclampsia in high risk women trial were used to measure serial sTNF-R1 and sTNF-R2 (enrollment, 24-28 week's gestation) in 986 women (577 also sampled at 34-38 weeks). RESULTS:Preeclampsia incidence was 21.2%. sTNF-R2 levels were higher at enrollment (P = .02) and weeks 24-28 (P = .01) in women who eventually developed preeclampsia. The magnitude of increase from baseline of both receptors was significantly greater in women who developed preeclampsia in the future. Women with week 24-28 sTNF-R2 levels in the highest quartile had significantly increased odds to develop preeclampsia (P = .03 vs quartile 1). This association was observed in the placebo but not the aspirin arm (P <or= .002). Sensitivities and positive predictive values were low. CONCLUSION: sTNF-R2 levels are elevated prior to overt preeclampsia, suggesting a pathogenetic role for these proinflammatory cytokines.
Authors: Elbert-Jaap I Schipper; Antoinette C Bolte; Casper G Schalkwijk; Herman P Van Geijn; Gustaaf A Dekker Journal: J Matern Fetal Neonatal Med Date: 2005-11
Authors: N Naccasha; M T Gervasi; T Chaiworapongsa; S Berman; B H Yoon; E Maymon; R Romero Journal: Am J Obstet Gynecol Date: 2001-11 Impact factor: 8.661
Authors: Cissy Chenyi Zhou; Roxanna A Irani; Yujin Zhang; Sean C Blackwell; Tiejuan Mi; Jiaming Wen; Harnath Shelat; Yong-Jian Geng; Susan M Ramin; Rodney E Kellems; Yang Xia Journal: Circulation Date: 2010-01-11 Impact factor: 29.690
Authors: Scott W Walsh; William H Nugent; Kellie J Archer; Marwah Al Dulaimi; Sonya L Washington; Jerome F Strauss Journal: Reprod Sci Date: 2021-05-06 Impact factor: 3.060